counter-generics

7.31.2014 Lifecycle Management

Biosimilars, Biobetters and Captain America: The Future of Biosimilars in a Future World of Biobetters

By Natalie DeMasi, Research Analyst After being untouchable for decades, US biologics companies are finally facing biosimilar competition.  Well, sort of.  Cutting Edge Information’s report on counter-generics strategies found that the high...
 

7.18.2014 Lifecycle Management

Using the Buddy System: Finding a Quality Partner for Generics and Counter-Generics Strategies

By Victoria Cavicchi, Research Analyst Ending product patents and generic competition are very real challenges in the pharmaceutical landscape. With limited counter-generics strategies, partnerships with generics companies can be an effective solution...
 

7.30.2013 Lifecycle Management

Sandoz Aims to Launch Biosimilar Version of Enbrel

By Jennifer Harrell, Research Analyst Sandoz, a generic subsidiary of Novartis and an industry leader in the development of follow-on biologics, is launching a Phase III clinical trial of a biosimilar version of Amgen’s Enbrel (etanercept).  Enbrel...
 

6.28.2013 Portfolio Management

Pfizer and Sun Settlement: Bad Omen for “At Risk” Generics Launches

By Christie Shilling, Research Analyst Once upon a time, a generics pharmaceutical company launched a generic version of another company’s branded product before patent expiration. Many years passed, with both companies in court fighting over...
 

5.21.2013 Lifecycle Management

Less Is Definitely Not More for Counter-Generics Strategies

By Christie Shilling, Research Analyst We have a running joke among the researchers at Cutting Edge Information.  Many of the key findings from our research can be boiled down to one phrase: Start Early.  Our usual advice for pharmaceutical companies...
 

7.26.2012 Lifecycle Management

Counter-Generics Strategies

With patents expiring right and left, pharmaceutical companies are looking for every possible tool to slow revenue losses. Counter-generic strategies are one method to maintain market share, however temporary. Even a period of six months when no generic versions...
 

1.3.2012 Lifecycle Management

Pfizer Aims to Retain Lipitor Patients for a Little Longer

By Jeremy Spivey,Senior Research Analyst After years of nurturing its global blockbuster and trying to prepare for patent expiration, Pfizer's Lipitor is finally open to direct generic competition in the United States. Ranbaxy, which has 180 days of...
 

11.7.2011 Portfolio Management

Portfolio Managers Need to Think at Least 10 Years Ahead

By Michelle Vitko,Research Analyst The earlier pharmaceutical companies begin mapping out their portfolio management options, the more strategies will be available to them and the more success they will have in general. In fact, a senior director at a...
 

10.13.2011 Lifecycle Management

Pharmaceutical Brand Defense Strategies: Pediatric Exclusivity

By Ryan McGuire,Senior Research Analyst This is the third installment in a blog series focusing on counter-generic strategies. You can read part 1 about the patent cliff and the second part on patent litigation. Under the FDA's Modernization Act Continue...
 

9.21.2011 Lifecycle Management

Pharmaceutical Brand Defense Strategies: Patent Litigation

By Ryan McGuire,Senior Research Analyst This is the second installment in a blog series focusing on counter-generic strategies. Read the first part here. Litigation is a natural response for pharmaceutical and biotechnology companies that find their...